Free Trial
NASDAQ:ATYR

aTyr Pharma Q2 2025 Earnings Report

aTyr Pharma logo
$6.03 +0.77 (+14.64%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$6.24 +0.22 (+3.57%)
As of 09/12/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

aTyr Pharma EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.18
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

aTyr Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

aTyr Pharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

aTyr Pharma's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

aTyr Pharma Earnings Headlines

Analysts Set aTyr Pharma, Inc. (NASDAQ:ATYR) Price Target at $23.25
Why Trump’s “Smart Dollar” could rewrite the rules
MUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.tc pixel
See More aTyr Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like aTyr Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on aTyr Pharma and other key companies, straight to your email.

About aTyr Pharma

aTyr Pharma (NASDAQ:ATYR) is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling. Its lead program, ATYR1923, is being investigated for the treatment of pulmonary sarcoidosis, and additional pipeline candidates are advancing in preclinical and early clinical studies for oncology and neuromuscular disorders. aTyr’s platform allows for the rapid screening of protein interactions and the engineering of modulators with potential applications across multiple therapeutic areas.

Founded in 2005, aTyr Pharma completed its initial public offering in 2015 and has since entered into strategic collaborations to accelerate the development and potential commercialization of its product candidates. The company’s research and development activities span North America and Europe, and its leadership team brings together expertise in protein therapeutics, immunology, and clinical development. aTyr continues to leverage its platform to address unmet medical needs and to expand its pipeline through internal discovery and external partnerships.

View aTyr Pharma Profile

More Earnings Resources from MarketBeat